Eton Pharmaceuticals Inc ETON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ETON is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $3.72
- Day Range
- $3.36–3.75
- 52-Week Range
- $2.42–5.81
- Bid/Ask
- $3.14 / $4.00
- Market Cap
- $88.24 Mil
- Volume/Avg
- 153,225 / 61,800
Key Statistics
- Price/Earnings (Normalized)
- 37.20
- Price/Sales
- 3.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 30
- Website
- https://www.etonpharma.com
Comparables
Valuation
|
Metric
|
ETON
|
CRNX
|
INVA
|
|---|---|---|---|
Price/Earnings (Normalized) | 37.20 | — | 9.42 |
Price/Book Value | 6.17 | 6.44 | 1.36 |
Price/Sales | 3.01 | 736.42 | 4.20 |
Price/Cash Flow | 29.64 | — | 7.80 |
Price/Earnings
ETON
CRNX
INVA
Financial Strength
|
Metric
|
ETON
|
CRNX
|
INVA
|
|---|---|---|---|
Quick Ratio | 1.53 | 12.92 | 8.51 |
Current Ratio | 1.65 | 13.07 | 10.42 |
Interest Coverage | — | — | 9.81 |
Quick Ratio
ETON
CRNX
INVA
Profitability
|
Metric
|
ETON
|
CRNX
|
INVA
|
|---|---|---|---|
Return on Assets (Normalized) | 5.39% | −38.81% | 14.79% |
Return on Equity (Normalized) | 10.50% | −44.79% | 29.29% |
Return on Invested Capital (Normalized) | 5.51% | −45.62% | 16.71% |
Return on Assets
ETON
CRNX
INVA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Ynphhzfky | Dwbk | $76.9 Bil | |
MKKGY
| Merck KGaA ADR | Kpszkrcjr | Klsnfr | $72.0 Bil | |
HLN
| Haleon PLC ADR | Zdskhcpf | Gtwyx | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Zfzltzxt | Tnwq | $17.9 Bil | |
VTRS
| Viatris Inc | Bvbfnrx | Sgjs | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Jzmfbyqj | Wqlfy | $11.7 Bil | |
CTLT
| Catalent Inc | Bhspbpyv | Lsjmz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Xdwjrmpt | Blh | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Zbqygnlwx | Kywpz | $4.0 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xklkxltf | Cmvzwqf | $3.5 Bil |